Skip to main
ANGO

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc is demonstrating robust growth in its customer base, particularly with its Auryon product line in both the office-based labs (OBL) and hospital settings, contributing positively to the average selling price (ASP). The company is achieving a notable gross margin improvement of 52.5%, driven by its manufacturing initiatives scheduled for completion in January 2026 and a favorable revenue mix shift towards higher Med-Tech sales. Management's confidence in ongoing product demand is supported by new customer acquisitions, increased utilization in existing accounts, and successful price increases, indicating a sustainable growth trajectory.

Bears say

AngioDynamics Inc. faces significant financial challenges, as management has projected $4 million to $6 million in tariff headwinds that could impact overall profitability. Additionally, the company anticipates pressure on its inventory for the second half of 2026 due to rising raw material costs, which may further strain margins. While recent sales of NanoKnife disposables exceeded expectations, the reliance on capital sales raises concerns about long-term disposable demand sustainability.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.